Differential behavior of conformational dynamics in active and inactive states of cannabinoid receptor 1 revealed by microsecond molecular dynamics simulation

by Isu, U. H.; Polasa, A.; Moradi, M.

Cannabinoid receptor 1 (CB1) is a G protein-coupled receptor (GPCR) that plays a pivotal role in numerous physiological processes, including pain modulation, appetite regulation, and neuronal signaling. Understanding the conformational changes and dynamics associated with CB1 is crucial for the development of targeted therapeutics aimed at modulating their signaling pathways. In this study, we employed microsecond-scale molecular dynamics (MD) simulations to investigate the dynamic differences in the structural ensembles of active and inactive CB1 states. By analyzing the trajectories obtained from the MD simulations, we explored the conformational changes and structural dynamics of CB1 at an atomistic level. Despite traditional models, inactive CB1 exhibited substantially greater conformational heterogeneity compared to the more rigid active state when both were unbound. Our results revealed significant conformational rearrangements, predominantly observed in the TM7 transmembrane helices, emphasizing its crucial role in the dynamic behavior of CB1. We also identified key electrostatic interactions that contribute to the conformational differences between the active and inactive states of CB1, specifically influenced by TM7. These interactions play a vital role in stabilizing specific conformations and modulating the receptor’s activity. This study underscores the importance of considering the dynamic aspects of CB1, as it provides valuable insights into the structural flexibility of transmembrane helices in different states. The observed conformational changes and dynamics highlight potential sites that could be targeted for the development of selective and efficient CB1 modulators. The findings presented in this study contribute to our overall understanding of CB1 receptor dynamics and have the potential to inform the design and optimization of therapeutic agents targeting CB1, thus offering new avenues for drug discovery and development.